Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging | Zendy

Jeremy J. Erasmus | Zendy; Eric Rohren | Zendy; Stephen G. Swisher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging

Author(s) -

Jeremy J. Erasmus,

Eric Rohren,

Stephen G. Swisher

Publication year - 2009

Publication title -

proceedings of the american thoracic society

Language(s) - English

Resource type - Journals

eISSN - 1943-5665

pISSN - 1546-3222

DOI - 10.1513/pats.200806-059lc

Subject(s) - medicine , positron emission tomography , lung cancer , positron emission tomography computed tomography , radiology , cancer , tomography , nuclear medicine , pathology

Positron emission tomography (PET) imaging using (18)F-2-deoxy-D-glucose, a D-glucose analog labeled with fluorine-18 (FDG-PET), is being evaluated in the assessment of prognosis and therapeutic response in patients with non-small cell lung cancer. FDG-PET imaging has the potential to allow more appropriate selection of patients for surgical resection and for neoadjuvant and aduvant chemotherapy as well as chemoradiation. Currently, the absence of standardization in how FDG-PET images are obtained and interpreted limits its widespread clinical utility. Although prospective multi-institutional trials and standardization of FDG-PET imaging protocols are required for the true utility to be determined, the evolving experience with FDG-PET imaging indicates a greater and integral role in treatment decisions. This article will discuss the assessment of prognosis and treatment response in patients with non-small cell lung cancer using FDG-PET, and will emphasize potential advantages and limitations in clinical management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research